Early intra-aortic balloon pump in heart failure complicated by cardiogenic shock: The Altshock-2 randomized clinical trial Reported from ACC
Early intra-aortic balloon pump in heart failure complicated by cardiogenic shock: The Altshock-2 randomized clinical trial
Reported from ACC.25
31 MAR 2025
The Altshock-2 trial investigated the efficacy of early intra-aortic balloon pump (IABP) implantation in patients with acute decompensated heart failure complicated by cardiogenic shock. Key points from the study include:
1. Study Design: A prospective, randomized, multicenter, open-label trial with blinded outcome assessment.
2. Patient Population: Included patients with hypotension or hypoperfusion , left ventricular ejection fraction <35%, randomized within 6 hours of cardiogenic shock diagnosis.
3. Intervention: Patients were assigned to early IABP implantation or standard vasoactive treatment.
4. Results: No significant difference in primary endpoint (81% in IABP group vs. 75% in control; P=0.45).
5. Safety: Higher rates of bleeding and vascular complications in the IABP group.
The study concluded that early IABP implantation did not offer additional benefit over standard care in this patient population.
